A 14 ‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma

Conclusions and clinical relevance: The 10 differential proteins identified by SRM have biological significance in cancer progression. The final signature of 14 proteins identified by SRM could be used to identify AJCC Stage III melanoma patients likely to have poor outcomes who may benefit from adjuvant systemic therapy.This article is protected by copyright. All rights reserved

Source: Proteomics. Clinical Applications - December 11, 2017 Category: Biochemistry Authors: Erin K. Sykes, Cassandra E. McDonald, Shila Ghazanfar, Swetlana Mactier, John F. Thompson, Richard A. Scolyer, Jean Y. Yang, Graham J. Mann, Richard I. Christopherson Tags: RESEARCH ARTICLE Source Type: research